Summit Extends Gains as Cancer Drug Outperforms BeiGene's Tevimbra

Seeking Alpha02:22

Express News | Hong Kong stocks in the Biomedical sector are gaining strength again, with AKESO rising over 10%, Genscript Biotech increasing nearly 10%, ZAI LAB up more than 7%, and WUXI BIO and WUXI APPTEC both rising close to 5%.

BreakingsApr 23 09:42

U.S. stock market close | Hopes for easing trade relations helped U.S. stocks rebound, with three major Indexes all rising over 2.5%; Growth Tech stocks collectively rose, with Tesla increasing by 4.6%; Chinese concept stocks performed well, with Alibaba

The China Concept Index rose by 3.7%, with PDD Holdings, NIO, and Xpeng Autos all increasing by over 4%. Following trade news, the yield on ten-year U.S. Treasuries hit a daily low, while the USD hit a daily high; the Swiss Franc fell by over 1% during the day. Bitcoin briefly surged nearly 5000 dollars, surpassing the 0.091 million mark. Crude Oil Product rebounded, approaching a two-week high, with U.S. oil rising by more than 3% at one point.

wallstreetcnApr 23 07:07

Express News | Hong Kong biotechnology stocks surged initially, with Genscript Biotech rising over 18%, Liatris Pharma and REMEGEN rising over 10%, and ZAI LAB rising over 6%.

BreakingsApr 22 09:37

U.S. stocks closed | Trump blasts Powell, scaring the market, with all three major U.S. indices dropping over 2%; the seven tech giants collectively fell, with Tesla down nearly 6% and NVIDIA down over 4%.

The three major U.S. stock indices all closed down more than 2%, with the Nasdaq dropping nearly 4% at one point. After the Earnings Reports, Tesla fell 6% and NVIDIA dropped 4.5%. UnitedHealth plummeted 27% in the two days after its Earnings Reports, leading the Dow. The Chinese concept Index narrowly rebounded by 0.2%, with NIO rising over 2% and Alibaba up over 1%. The Swiss franc rose over 1%, reaching a ten-year high. Bitcoin soared nearly $4,000, surpassing the 0.088 million mark at one point. Crude Oil Product dropped over 3% at one point.

wallstreetcnApr 22 07:07

After the unsuccessful privatization of HENLIUS, FOSUN PHARMA took action to increase its Shareholding. Is it continuing to send Bullish signals? | Quick read of the announcement.

① After the privatization failure last year, FOSUN PHARMA continues to signal its bullish outlook on HENLIUS, and today increased its shareholding in HENLIUS; ② HENLIUS had impressive performance last year, and recently has been actively releasing positive news.

cls.cnApr 21 20:21